Skip to main content
Equibles
IRLA logo

IRLA · IRulya Therapeutics Inc. · Metrics

Track IRLA — free

Use IRLA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRLA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$40.27 +5.82 (+16.89%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Factoring in these potential cash payments, based on its current operating plan, the Company believes that its cash and cash equivalents balance will not be sufficient to fund operations and capital expenditures for at least the twelve months following the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$40.96M
Shares
1.02M
Volume · Oct 20 316.95K Avg daily vol (3M) 34.16K

IRLA metrics

52 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$40.27
Market cap
$40.96M

Price action

20 metrics
Price change (1W)
+6.3%
Price change (30D)
+11.1%
Price change (3M)
+83.0%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
81.9%
Annualized volatility (3M)
84.2%
Beta
—
RSI (14D)
59.7
Price vs SMA 50
+11.4%
Price vs SMA 200
—
Avg volume (3M)
29,701
Relative volume
1.4
Average dollar volume
$853,676

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
-134.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-263.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-08-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$127.16M
Net income (TTM)
−$92.48M
Trailing 12 months
Diluted EPS (TTM)
$-153.56
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-164.11
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-125.83
Operating cash flow per diluted share (TTM)
$-94.16
Free cash flow per diluted share (TTM)
$-94.45
Capital expenditures per diluted share (TTM)
$0.29
R&D per diluted share (TTM)
$91.05
Stock compensation per diluted share (TTM)
$13.70
Book value per share
$-128.18

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,527.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-74.6%
Debt / equity
—
Current ratio
14.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$47.00M
Quick ratio
14.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$17.75M
Latest balance sheet
Cash & equivalents
$115.98M
Total assets
$124.00M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$46.92M
Capital expenditures (TTM)
$78,000
R&D (TTM)
$32.99M
SG&A (TTM)
—
Stock compensation (TTM)
$15.82M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
28
13F filer change QoQ
-20
Institutional ownership
60.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
37.3%
Private-fund adviser ownership
33.5%
Active holders' share change QoQ
+389.2%
Holder tenure
2.7
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
1.2%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1662774 Visit website Investor relations